Skip to main content

Table 2 NCI-CTC

From: Assessment of disease control rate and safety of sorafenib in targeted therapy for advanced liver cancer

Item

Grade

Explanations

Nausea

0

No nausea events occurred.

1

Some experienced mild nausea but it did not affect their appetite, and their food intake remained normal.

2

Some experienced mild nausea but were still able to eat, although their food intake decreased.

3

Severe nausea was present, making it impossible to eat.

Peripheral neurotoxicity

0

Normal reflexes observed.

1

Diminished tendon reflexes.

2

Severe sensory abnormalities and mild weakness.

3

Significant motor impairment noted.

4

Patient is paralyzed.

Oral ulceration

0

Patient shows no abnormal signs.

1

Mild ulceration or erythema, but no pain reported.

2

Erythema with swelling and pain, ulceration present but still able to eat.

3

Erythema with swelling and pain, extensive ulceration, unable to eat.

4

Erythema with swelling and pain, extensive ulceration, unable to eat, requiring urgent nutritional support treatment.

Vomiting

0

No vomiting reported.

 

1

Vomiting once within a day.

 

2

Vomiting 2–5 times within a day.

 

3

Vomiting 6–10 times within a day.

 

4

Vomiting more than 10 times within a day, requiring intravenous fluid therapy.